1-8 of 8
Aimee E Jackson
Close
Sort by
Journal Articles

Ibrutinib as part of risk-stratified treatment for post-transplant lymphoproliferative disorder: The phase 2 TIDaL trial

Sridhar Chaganti, Shanna Maycock, Graham McIlroy, Aimee E Jackson, Rebecca Bishop, Sarah Johnson, Edward Kanfer, Shireen Kassam, Kate Cwynarski, David J Wrench, Arvind Arumainathan, Christopher P Fox, Rod J Johnson, Pamela McKay, Shankara Paneesha, Clare Rowntree, Constantine Balotis, Graham P. Collins, Andrew J Davies, Josh Wright, Sarah Burns, Dr, Arian Dominic John Laurence, Keith Wheatley, Tobias Menne
Journal: Blood
Blood blood.2024023847.
https://doi.org/10.1182/blood.2024023847
Published: 2024
Includes: Supplemental data
Journal Articles

Exploring Genotype:Phenotype Correlations at Baseline and at One Year for ET and PV Patients in the Majic Study

Chandan Saha, Carolyn Mead-Harvey, Adam J. Mead, Rebecca H. Boucher, Sonia Fox, Isaak Ailts, Christina Yap, Aimee E Jackson, Joanne Ewing, Jason Coppell, Steve Knapper, Mark W. Drummond, Anna L Godfrey, Amylou C. Dueck, Ruben A. Mesa, Robyn Scherber, Mary Frances McMullin, Holly L. Geyer, Claire N. Harrison
Journal: Blood
Blood (2021) 138 (Supplement 1): 1507.
https://doi.org/10.1182/blood-2021-151568
Published: 2021
Journal Articles

Post-Transplant MRD Status and T Cell Chimerism Predict Outcomes in Patients Allografted for AML/MDS-a Prospective Analysis from the UK NCRI Figaro Trial

(Justin) Ching Ting Loke, Nicholas McCarthy, Aimee E Jackson, Shamyla Siddique, Andrea Hodgkinson, John Mason, Charles Crawley, Maria H Gilleece, Andy Peniket, Rachel Elizabeth Protheroe, Rahuman Salim, Eleni Tholouli, Keith Wilson, Georgia M. Andrew, Richard Dillon, Naeem Khan, Victoria Potter, Pramila Krishnamurthy, Charles Craddock, Sylvie D Freeman
Journal: Blood
Blood (2021) 138 (Supplement 1): 415.
https://doi.org/10.1182/blood-2021-149269
Published: 2021
Journal Articles

Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]

Mark W. Drummond, PhD FRCPath, Charlotte Gaskell, BSc, MSc, Claire Harrison, DM, FRCP, FRCPath, Adam J. Mead, MD PhD, Christina Yap, PhD CStat, Aimee E Jackson, BSc, MSc, Jennifer Byrne, FRCP, FRCPath, PhD, Fiona J Clark, FRCP, FRCPath, Srinivasan Narayanan, FRCP, FRCPath, David Bowen, MD, Tim C.P Somervaille, PhD FRCP, FRCPath, Emma Gudgin, MBBS, MRCP, FRCPath, PhD, Dragana Milojkovic, Rachel S Fletcher, PhD, Charlotte K Brierley, MRCP, MD, Steve Knapper, BMBCh, MRCP, FRCPath, DM
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-138437
Published: 2020
Journal Articles

AVAIL-T: A Phase 2a Trial of Avelumab, and Anti-PD-L1 Antibody, in Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL)

Matthew J Ahearne, Charlotte Gaskell, BSc, MSc, Aimee E Jackson, BSc, MSc, Clare Morland, PhD, Louise Hopkins, Nadia Nawaz, Matthew A Timmins, Christopher P Fox, MD PhD, Graham P. Collins, MD DPhil, Andrew Davies, David John Lewis, MD, Kate Cwynarski, Kim Linton, MBChB, MRCP, PhD, Pam McKay, MD, Rod Johnson, Simon D. Wagner
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-136061
Published: 2020
Journal Articles

The Sequential Flamsa-Bu Conditioning Regimen Does Not Improve Outcome in Patients Allografted for High Risk Acute Myeloid and Myelodysplasia Irrespective of Pre-Transplant MRD Status: Results of the UK NCRI Figaro Trial

Charles Craddock, FRCP, FRCPath, Aimee E Jackson, MSc, Ram K Malladi, FRCPath, Maria H Gilleece, MD FRCPath, MB, BSc, FRCP, Andy Peniket, MD, Rahuman Salim, MRCP, FRCPath, Eleni Tholouli, MD PhD, Victoria Potter, MD PhD, Charles R Crawley, Rachel Elizabeth Protheroe, FRCPath,PhDMBBS,FRCP, Anne Parker, MD FRCP, BSc, FRCPath, Keith Wilson, FRCPath, MRCP, MBBS, Jiri Pavlu, MDMRCP,FRCPath, Sandeep Nagra, MBChB, Shamyla Siddique, BSc.(Hons.), MPhil, Andrea Hodgkinson, BSc(Hons),PhD, John Mason, Keith Wheatley, DPhil, Nigel H. Russell, MD, Sylvie D. Freeman, MBChB, DPhil
Journal: Blood
Blood (2019) 134 (Supplement_1): 2031.
https://doi.org/10.1182/blood-2019-125646
Published: 2019
Journal Articles

A Phase I/II Dose-Escalation Study of Thiotepa-Based Immunochemotherapy in Relapsed/Refractory Primary Central Nervous System Lymphoma; The Tier Trial

Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD, Ayesha S Ali, MSc, Dorothee Auer, MD DM, PhD, Steffi Thust, MD FRCR, Aimee E Jackson, MSc, Louise Hopkins, BSc, MRes, Catherine Thomas, PhDBSc, Nicolas Martinez-Calle, MD MSc, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Shireen Kassam, MD, Josh Wright, MD, David Lewis, PhD FRCPath, BSc, Andres JM Ferreri, MD, Sridhar Chaganti, MDPhDMRCP,FRCPath, Jeffery Smith, MBChB BMedSci MRCP FRCPath, Kim Linton, MBChB PhD, Ian Chau, MD, Dominic J. Culligan, MD, Andrew Davies, MD PhD, Roderick Johnson, MD, Kate Cwynarski, PhDMD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2879.
https://doi.org/10.1182/blood-2019-122830
Published: 2019
Journal Articles

Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study

Jelena Jovanovic, PhD, Nicola Potter, PhD, Anju Kanda, MSc, Claire Schwab, PhD, Aimee E Jackson, MSc, Richard Dillon, MA, PhD MRCP, FRCPath, Anna Lawson, BSc, Manohursingh Runglall, MSc, Paresh Vyas, MD PhD, Paul Virgo, Geoff Shenton, Nicholas Heaney, Beki James, MD, Katharine Patrick, MD, Persis J Amrolia, FRCP, FRCPath, PhD, Jean-Hugues Dalle, MD PhD, Gerard Michel, MD, Andrew S. Moore, MBBS,FRACP,PhD, Hélène Lapillonne, MD PhD, Claude Preudhomme, PharmD, PhD, Guy Leverger, MD, Owen P Smith, MD, Andre Baruchel, MD, Yves Bertrand, MD, Arnaud Petit, MD PhD, Keith Wheatley, DPhil, Pamela R. Kearns, PhDFRCPC, Christine J. Harrison, PhD FRCPath, Brenda Gibson, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1393.
https://doi.org/10.1182/blood-2019-125257
Published: 2019